ImaRx Therapeutics Postpones Release of First Quarter 2008 Financial Results Live Webcast and Conference Call Scheduled for Thursday, May 15th at 5 PM ET

TUCSON, Ariz., May 13 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. today announced that the Company has postponed its live webcast and conference call to Thursday, May 15, 2008, at 5:00 p.m. ET to discuss first quarter 2008 financial results; this call was originally scheduled for Tuesday, May 13, 2008, at 5:00 p.m. ET.

The live webcast can be accessed through ImaRx's corporate website at www.imarx.com and will be archived on the website for 14 days following the event.

Interested parties may access the conference call by dialing (877) 407-4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through May 22, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 284385).

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. The Company's commercialization efforts are currently focused on its product, urokinase, for the treatment of acute massive pulmonary embolism.

CONTACT: Investors, Sara Ephraim, +1-646-536-7002,
sephraim@theruthgroup.com, or Media, Jason Rando, +1-646-536-7025,
jrando@theruthgroup.com, both of The Ruth Group, for ImaRx Therapeutics,
Inc.

Web site: http://www.imarx.com/